HIV prevention medication offered in regular doctor visits
Part of Immune system & allergy, Infections clinical trials.
This study looks at prescribing PrEP (medication to prevent HIV) in regular doctor's offices. It may help you get easier access to prevention if you're at higher risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are HIV-negative (confirmed by a test within the past week or an undetectable viral load).
- You are seeing a general practitioner for one of these: starting PrEP for the first time, getting a renewal after at least 4 months without it, or for another reason but you are at risk and need PrEP.
- You belong to a higher-risk group (e.g., men who have sex with men, transgender people with male partners, people from high-HIV-prevalence regions, sex workers, people who inject drugs, or have partners from these groups).
- You have a high-exposure situation (e.g., many partners, partner with uncontrolled HIV, no condoms, sexual violence, or recent STIs or emergency prevention).
- You are not allergic to PrEP medications and have no severe kidney problems (creatinine clearance below 60).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps young people who are at risk for HIV get on PrEP—a daily pill or shot that prevents HIV. It tests different ways to help you start and stay on PrEP, with care available at clinics or in your community.
This study tests whether pharmacies can offer HIV prevention medications (PrEP/PEP) with remote nurse support. It aims to make HIV prevention easier to access in the community.
This study helps pharmacies that do not yet offer PrEP (the daily medicine that prevents HIV) learn how to start. It provides training and support on the basics of PrEP and how to make it financially sustainable.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
This trial checks how well PrEP pills (TDF/FTC) prevent HIV in people who are at high risk and are HIV-negative. It may help you understand whether PrEP is a good prevention option for your situation.
This trial tests a program where HIV testing counselors help family planning patients learn about and get PrEP, a daily pill that prevents HIV. It aims to make PrEP easier to access in clinics you may already visit.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.